Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;12(7):1625-1627.
doi: 10.21037/tlcr-23-222. Epub 2023 Jun 14.

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?

Barbara Melosky  1
Affiliations
Editorial

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?

Barbara Melosky. Transl Lung Cancer Res. .
No abstract available

Keywords: EGFR; Lung cancer; mutation cure.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-222/coif). The author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Updated Kaplan-Meier analysis of DFS among patients with stage IB-IIIA NSCLC (per investigator assessment). Tick marks indicate censored data. Source from (1). DFS, disease-free survival; CI, confidence interval; HR, hazard ratio; NC, not calculated; NSCLC, non-small cell lung cancer.
See this image and copyright information in PMC

Comment on

References

    1. Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol 2023;41:1830-40. 10.1200/JCO.22.02186 - DOI - PMC - PubMed
    1. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020;383:1711-23. 10.1056/NEJMoa2027071 - DOI - PubMed
    1. Joensuu H, Eriksson M, Sundby Hall K, et al. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol 2020;6:1241-6. 10.1001/jamaoncol.2020.2091 - DOI - PMC - PubMed
    1. Casali PG, Le Cesne A, Velasco AP, et al. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)(☆). Ann Oncol 2021;32:533-41. 10.1016/j.annonc.2021.01.004 - DOI - PubMed
    1. Wu YL, Zhong W, Wang Q, et al. Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104). J Clin Oncol 2017;35:8500. 10.1200/JCO.2017.35.15_suppl.8500 - DOI